Intellia Therapeutics, Inc. (NTLA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1240494,
    "name": "Intellia Therapeutics, Inc.",
    "stock_name": "Intellia Therapeutics, Inc.",
    "full_name": "Intellia Therapeutics, Inc.",
    "name_url": "stocks-analysis/intellia-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "9.74",
    "chg": 1.64,
    "chgp": "20.25%",
    "dir": 1,
    "prev_price": "8.10",
    "mcapval": "1,270.99",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US45826J1051",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.58 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/intellia-therapeutics-inc-1240494-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Intellia Therapeutics Stock Hits Day Low of $8.96 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/intellia-therapeutics-stock-hits-day-low-of-896-amid-price-pressure-3686572",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IntelliaTherape_priceRelatedfactors_3686572.png",
        "date": "2025-11-10 17:53:44",
        "description": "Intellia Therapeutics, Inc. has faced significant stock volatility, hitting an intraday low and experiencing a substantial year-to-date decline. The company reported negative operating cash flow and a decrease in net sales, with long-term growth prospects appearing limited amid ongoing challenges in the pharmaceuticals and biotechnology sector."
      },
      {
        "title": "Intellia Therapeutics Faces Weak Start with 10.21% Gap Down Amid Market Concerns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/intellia-therapeutics-faces-weak-start-with-1021-gap-down-amid-market-concerns-3712440",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/IntelliaTherape_gapdown_3712440.png",
        "date": "2025-10-31 16:45:40",
        "description": "Intellia Therapeutics, Inc. opened with a notable loss, reflecting a significant downturn over the past month. The company, with a market capitalization of approximately USD 1.27 billion, is currently loss-making and faces mixed technical indicators amid cautious market sentiment in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Intellia Therapeutics Stock Hits Day Low of $24.14 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/intellia-therapeutics-stock-hits-day-low-of-2414-amid-price-pressure-3641344",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/IntelliaTherape_priceRelatedfactors_3641344.png",
        "date": "2025-10-23 17:38:24",
        "description": "Intellia Therapeutics, Inc. saw a notable decline in stock value, contrasting with the stable performance of the S&P 500. The company has faced significant challenges, including a steep drop in operating profit and negative cash flow, while its market capitalization stands at USD 1,271 million."
      },
      {
        "title": "Intellia Therapeutics Hits Day High with 8.49% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/intellia-therapeutics-hits-day-high-with-849-surge-in-stock-price-3626740",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/IntelliaTherape_priceRelatedfactors_3626740.png",
        "date": "2025-10-16 19:04:19",
        "description": "Intellia Therapeutics, Inc. saw a notable increase in its stock performance on October 15, 2025, reaching an intraday high. While the company has shown impressive short-term gains and outperformed the S&P 500, it faces significant long-term financial challenges, including negative operating profit growth and low cash flow."
      },
      {
        "title": "Intellia Therapeutics Hits Day High with 19.72% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/intellia-therapeutics-hits-day-high-with-1972-surge-in-stock-price-3608139",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/IntelliaTherape_priceRelatedfactors_3608139.png",
        "date": "2025-10-09 21:01:20",
        "description": "Intellia Therapeutics, Inc. saw a notable stock increase on October 8, 2025, reaching an intraday high of USD 26.45. The company has demonstrated impressive weekly and monthly growth, though it faces long-term challenges with a significant decline over three years and ongoing financial pressures."
      },
      {
        "title": "Intellia Therapeutics Hits New 52-Week High at $26.45",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/intellia-therapeutics-hits-new-52-week-high-at-2645-3608048",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/IntelliaTherape_priceRelatedfactors_3608048.png",
        "date": "2025-10-09 20:22:24",
        "description": "Intellia Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. Despite underperforming compared to the S&P 500 over the past year, the company's market capitalization is notable. Financial metrics indicate ongoing challenges, including losses and a negative return on equity."
      },
      {
        "title": "Intellia Therapeutics Hits New 52-Week High of $21.49",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/intellia-therapeutics-hits-new-52-week-high-of-2149-3601674",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/IntelliaTherape_priceRelatedfactors_3601674.png",
        "date": "2025-10-07 21:57:49",
        "description": "Intellia Therapeutics, Inc. has achieved a new 52-week high of USD 21.49, rebounding from a low of USD 5.90. Despite this milestone, the company has experienced an 11.77% decline over the past year, with a market capitalization of USD 1,271 million and ongoing financial challenges."
      },
      {
        "title": "Intellia Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/intellia-therapeutics-technical-trend-shifts-from-bullish-to-mildly-bullish-amid-stock-price-increase-3559618",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/IntelliaTherape_technicaldot_3559618.png",
        "date": "2025-09-23 16:18:38",
        "description": "Intellia Therapeutics, Inc. has recently revised its evaluation amid market fluctuations, with its stock price rising to $17.26. The company has shown significant volatility over the past year, with mixed technical indicators and strong short-term returns, while facing challenges in longer-term performance metrics."
      },
      {
        "title": "Intellia Therapeutics Hits Day High with 10.71% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/intellia-therapeutics-hits-day-high-with-1071-surge-in-stock-price-3559182",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/IntelliaTherape_priceRelatedfactors_3559182.png",
        "date": "2025-09-23 15:09:46",
        "description": "Intellia Therapeutics, Inc. has seen notable stock activity, with significant short-term gains over the past week and month, despite a longer-term decline. The company, categorized as a small-cap in the Pharmaceuticals & Biotechnology sector, faces challenges with negative return on equity and operating cash flow."
      }
    ],
    "total": 19,
    "sid": "1240494",
    "stock_news_url": "https://www.marketsmojo.com/news/intellia-therapeutics-inc-1240494"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Intellia Therapeutics Stock Hits Day Low of $8.96 Amid Price Pressure

2025-11-10 17:53:44

Intellia Therapeutics, Inc. has faced significant stock volatility, hitting an intraday low and experiencing a substantial year-to-date decline. The company reported negative operating cash flow and a decrease in net sales, with long-term growth prospects appearing limited amid ongoing challenges in the pharmaceuticals and biotechnology sector.

Intellia Therapeutics Faces Weak Start with 10.21% Gap Down Amid Market Concerns

2025-10-31 16:45:40

Intellia Therapeutics, Inc. opened with a notable loss, reflecting a significant downturn over the past month. The company, with a market capitalization of approximately USD 1.27 billion, is currently loss-making and faces mixed technical indicators amid cautious market sentiment in the Pharmaceuticals & Biotechnology sector.

Intellia Therapeutics Stock Hits Day Low of $24.14 Amid Price Pressure

2025-10-23 17:38:24

Intellia Therapeutics, Inc. saw a notable decline in stock value, contrasting with the stable performance of the S&P 500. The company has faced significant challenges, including a steep drop in operating profit and negative cash flow, while its market capitalization stands at USD 1,271 million.

Intellia Therapeutics Hits Day High with 8.49% Surge in Stock Price

2025-10-16 19:04:19

Intellia Therapeutics, Inc. saw a notable increase in its stock performance on October 15, 2025, reaching an intraday high. While the company has shown impressive short-term gains and outperformed the S&P 500, it faces significant long-term financial challenges, including negative operating profit growth and low cash flow.

Intellia Therapeutics Hits Day High with 19.72% Surge in Stock Price

2025-10-09 21:01:20

Intellia Therapeutics, Inc. saw a notable stock increase on October 8, 2025, reaching an intraday high of USD 26.45. The company has demonstrated impressive weekly and monthly growth, though it faces long-term challenges with a significant decline over three years and ongoing financial pressures.

Intellia Therapeutics Hits New 52-Week High at $26.45

2025-10-09 20:22:24

Intellia Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. Despite underperforming compared to the S&P 500 over the past year, the company's market capitalization is notable. Financial metrics indicate ongoing challenges, including losses and a negative return on equity.

Intellia Therapeutics Hits New 52-Week High of $21.49

2025-10-07 21:57:49

Intellia Therapeutics, Inc. has achieved a new 52-week high of USD 21.49, rebounding from a low of USD 5.90. Despite this milestone, the company has experienced an 11.77% decline over the past year, with a market capitalization of USD 1,271 million and ongoing financial challenges.

Intellia Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-09-23 16:18:38

Intellia Therapeutics, Inc. has recently revised its evaluation amid market fluctuations, with its stock price rising to $17.26. The company has shown significant volatility over the past year, with mixed technical indicators and strong short-term returns, while facing challenges in longer-term performance metrics.

Intellia Therapeutics Hits Day High with 10.71% Surge in Stock Price

2025-09-23 15:09:46

Intellia Therapeutics, Inc. has seen notable stock activity, with significant short-term gains over the past week and month, despite a longer-term decline. The company, categorized as a small-cap in the Pharmaceuticals & Biotechnology sector, faces challenges with negative return on equity and operating cash flow.

View All News